Share the post "DII Data: Stock Market today Insights for 22 Aug 2024"
Company Logo | Company | Client Name | Buy/Sell | Qty Traded | Price | Trader Name |
---|---|---|---|---|---|---|
Navigant Corporate Advisors | Alacrity Securities | Sell | 17K | 36.10 | Navigant Ir Services Private | |
Pnb Housing Finance | Asia Opportunities V (mauritius) | Sell | 7M | 866.70 | Government Of Singapore | |
Government Of Singapore | Buy | 1M | 866.05 | Asia Opportunities V (mauritius) | ||
Shriram Properties | Bnp Paribas Financial Markets | Buy | 853K | 126.85 | Graviton Research Capital Llp | |
Eris Lifesciences | Emerald Investments | Sell | 9M | 1201.00 | Infinity Partners | |
Niit | Hornbill Orchid India Fund | Sell | 3M | 118.00 | Pawar Family Trust | |
V2 Retail | India 2020 Fund Ii | Sell | 700K | 1056.17 | F3 Advisors Private | |
Kalyan Jewellers India | Motilal Oswal Mutual Fund | Buy | 9M | 539.10 | Highdell Investment | |
Nomura Funds Ireland Plc Nomura Funds Ireland India Equity Fund | Buy | 7M | 539.10 | Highdell Investment | ||
Nomura India Investment Fund Mother Fund | Buy | 11M | 539.10 | Highdell Investment | ||
Sanjivani Paranteral | Next Orbit Ventures Fund | Sell | 100K | 280.46 | Na | |
Milgrey Finance & Investment | Shreni Construction Private | Sell | 5100 | 40.46 | Multiplier Share & Stock Advisors Private |
The 17K shares of Navigant Corporate Advisors have been sold by the by Alacrity Securities through Domestic Investments at a price of ₹36.10 per shareand it is purchased by Navigant Ir Services Private at a price of ₹36.10 per share.
The 7M shares of Pnb Housing Finance have been sold by the by Asia Opportunities V (mauritius) through Domestic Investments at a price of ₹866.70 per shareand it is purchased by Government Of Singapore at a price of ₹866.70 per share.
The 853K shares of Shriram Properties have been purchased by the by Bnp Paribas Financial Markets through Domestic Investments at a price of ₹126.85 per shareand it is sold by Graviton Research Capital Llp at a price of ₹126.85 per share.
The 9M shares of Eris Lifesciences have been sold by the by Emerald Investments through Domestic Investments at a price of ₹1201.00 per shareand it is purchased by Infinity Partners at a price of ₹1201.00 per share.
The 1M shares of Pnb Housing Finance have been purchased by the by Government Of Singapore through Domestic Investments at a price of ₹866.05 per shareand it is sold by Asia Opportunities V (mauritius) at a price of ₹866.05 per share.
The 3M shares of Niit have been sold by the by Hornbill Orchid India Fund through Domestic Investments at a price of ₹118.00 per shareand it is purchased by Pawar Family Trust at a price of ₹118.00 per share.
The 700K shares of V2 Retail have been sold by the by India 2020 Fund Ii through Domestic Investments at a price of ₹1056.17 per shareand it is purchased by F3 Advisors Private at a price of ₹1056.17 per share.
The 9M shares of Kalyan Jewellers India have been purchased by the by Motilal Oswal Mutual Fund through Domestic Investments at a price of ₹539.10 per shareand it is sold by Highdell Investment at a price of ₹539.10 per share.
The 100K shares of Sanjivani Paranteral have been sold by the by Next Orbit Ventures Fund through Domestic Investments at a price of ₹280.46 per share.
The 7M shares of Kalyan Jewellers India have been purchased by the by Nomura Funds Ireland Plc Nomura Funds Ireland India Equity Fund through Domestic Investments at a price of ₹539.10 per shareand it is sold by Highdell Investment at a price of ₹539.10 per share.
The 11M shares of Kalyan Jewellers India have been purchased by the by Nomura India Investment Fund Mother Fund through Domestic Investments at a price of ₹539.10 per shareand it is sold by Highdell Investment at a price of ₹539.10 per share.
The 5100 shares of Milgrey Finance & Investment have been sold by the by Shreni Construction Private through Domestic Investments at a price of ₹40.46 per shareand it is purchased by Multiplier Share & Stock Advisors Private at a price of ₹40.46 per share.
Company Logo | Company | Client Name | Buy/Sell | Qty Traded | Price | Trader Name |
---|---|---|---|---|---|---|
Alkem Laboratories | Bnp Paribas Arbitrage -non Odi | Buy | 35K | 5732.15 | Samprada&nanhamati Singh Family Trust | |
Citigroup Global Markets Mauritius Private | Buy | 35K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Copthall Mauritius Investment -non Odi Account | Buy | 17K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Goldman Sachs Investments Mauritius I | Buy | 35K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Icici Prudential Life Insurance Company | Buy | 197K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Jm Financial Mutual Fund | Buy | 17K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Kotak Mahindra Mutual Fund | Buy | 61K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Morgan Stanley Asia Singapore Pte | Buy | 35K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Reliance Nippon Life Insurance Company | Buy | 61K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Societe Generale | Buy | 46K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Tata Mutual Fund | Buy | 87K | 5732.15 | Samprada&nanhamati Singh Family Trust | ||
Eris Lifesciences | Emerald Investments | Sell | 9M | 1201.00 | Infinity Partners | |
Kalyan Jewellers India | Fidelity Funds – Sustainable Asia Equity Ii Pool | Buy | 743K | 539.10 | Highdell Investment | |
Fidelity Investment Funds – Fidelity Sustainable Asia Equity Fund | Buy | 66K | 539.10 | Highdell Investment | ||
Government Of Singapore | Buy | 7M | 539.10 | Highdell Investment | ||
Hsbc Mutual Fund | Buy | 2M | 539.10 | Highdell Investment | ||
Invesco Mutual Fund A/c Invesco Tax Plan | Buy | 1M | 539.10 | Highdell Investment | ||
Monetary Authority Of Singapore | Buy | 1M | 539.10 | Highdell Investment | ||
Motilal Oswal Mutual Fund | Buy | 9M | 539.10 | Highdell Investment | ||
Nomura Funds Ireland Plc-asia Ex Japan High Conviction Fund | Buy | 1M | 539.10 | Highdell Investment | ||
Nomura India Investment Fund Mother Fund | Buy | 11M | 539.10 | Highdell Investment | ||
Sundaram Mutual Fund | Buy | 1M | 539.10 | Highdell Investment | ||
The Master Tr Bk Of Jpn As Trstee Of Fidelity Asia Eqty Mother Fd | Buy | 62K | 539.10 | Highdell Investment | ||
Niit | Hornbill Orchid India Fund | Sell | 3M | 118.00 | Pawar Family Trust |
Alkem Laboratories shares totaling 35K were purchased by the by Bnp Paribas Arbitrage -non Odi of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Alkem Laboratories shares totaling 35K were purchased by the by Citigroup Global Markets Mauritius Private of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Alkem Laboratories shares totaling 17K were purchased by the by Copthall Mauritius Investment -non Odi Account of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Eris Lifesciences shares totaling 9M were sold by the by Emerald Investments of Domestic Investments, with the transaction occurring at a price of ₹1201.00 per share. Subsequently, the shares were purchased by Infinity Partners at the same price per share.Kalyan Jewellers India shares totaling 743K were purchased by the by Fidelity Funds – Sustainable Asia Equity Ii Pool of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.Kalyan Jewellers India shares totaling 66K were purchased by the by Fidelity Investment Funds – Fidelity Sustainable Asia Equity Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Alkem Laboratories shares totaling 35K were purchased by the by Goldman Sachs Investments Mauritius I of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Kalyan Jewellers India shares totaling 7M were purchased by the by Government Of Singapore of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.Niit shares totaling 3M were sold by the by Hornbill Orchid India Fund of Domestic Investments, with the transaction occurring at a price of ₹118.00 per share. Subsequently, the shares were purchased by Pawar Family Trust at the same price per share.
Kalyan Jewellers India shares totaling 2M were purchased by the by Hsbc Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.Alkem Laboratories shares totaling 197K were purchased by the by Icici Prudential Life Insurance Company of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Kalyan Jewellers India shares totaling 1M were purchased by the by Invesco Mutual Fund A/c Invesco Tax Plan of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Alkem Laboratories shares totaling 17K were purchased by the by Jm Financial Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Alkem Laboratories shares totaling 61K were purchased by the by Kotak Mahindra Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Kalyan Jewellers India shares totaling 1M were purchased by the by Monetary Authority Of Singapore of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Alkem Laboratories shares totaling 35K were purchased by the by Morgan Stanley Asia Singapore Pte of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Kalyan Jewellers India shares totaling 9M were purchased by the by Motilal Oswal Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.Kalyan Jewellers India shares totaling 1M were purchased by the by Nomura Funds Ireland Plc-asia Ex Japan High Conviction Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Kalyan Jewellers India shares totaling 11M were purchased by the by Nomura India Investment Fund Mother Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.Alkem Laboratories shares totaling 61K were purchased by the by Reliance Nippon Life Insurance Company of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Alkem Laboratories shares totaling 46K were purchased by the by Societe Generale of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Kalyan Jewellers India shares totaling 1M were purchased by the by Sundaram Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.Alkem Laboratories shares totaling 87K were purchased by the by Tata Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.Kalyan Jewellers India shares totaling 62K were purchased by the by The Master Tr Bk Of Jpn As Trstee Of Fidelity Asia Eqty Mother Fd of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
PNB Housing Finance Limited
18,125.30
Net Sales
4,387.10
Net Profit
18,220.10
Total Income
12,632.80
Expenditure
1,023
Current Price
26,584
Market Cap
In PNB Housing Finance Limited's recent financial report, the data highlights a robust performance. Net sales reached ₹18,125.30 million, with total income of ₹18,220.10 million. The expenditure was ₹12,632.80 million, leading to a net profit of ₹4,387.10 million. Earnings per Share (EPS) for continuing operations were reported at ₹16.89. The financial overview also includes other income of ₹94.80 million, finance costs of ₹10,972.50 million, and employee benefit expenses totaling ₹838.70 million. Depreciation and amortization expenses were ₹133.10 million. Current and deferred taxes were recorded at ₹1,440.70 million and ₹-240.50 million, respectively. The total comprehensive income for the period was ₹4,217.60 million, and other comprehensive income net of taxes was ₹-169.50 million.
Valued at ₹26,584 crore, the company's stock trades at ₹1,023, with historical highs and lows of ₹1,110 / 600. The P/E ratio of 16.7 reflects a high stock valuation. The book value is ₹577, and the dividend yield is 0.00%. ROCE is at 9.24%, and ROE is 11.6%. The company’s minimal debt-to-equity ratio of 3.67 contrasts with its negative net cash flow of ₹-1,669 crore. The Piotroski score is 4.00, and the Graham Number of ₹892 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 1.78 indicates a premium valuation.
Shriram Properties Limited
1,539.60
Net Sales
174.60
Net Profit
2,109.00
Total Income
1,867.40
Expenditure
135
Current Price
2,307
Market Cap
The latest financial figures for Shriram Properties Limited indicate a strong performance. The company achieved net sales of ₹1,539.60 million and total income of ₹2,109.00 million for the quarter. Expenditure was ₹1,867.40 million, resulting in a net profit of ₹174.60 million. Earnings per Share (EPS) for continuing operations stood at ₹1.02. The report also shows other income of ₹569.40 million, finance costs of ₹267.60 million, and employee benefit expenses of ₹229.60 million. Depreciation and amortization expenses totaled ₹26.50 million. Current tax expense was ₹0.70 million and deferred tax expense was ₹98.10 million. Total comprehensive income for the period was ₹174.70 million, with other comprehensive income net of taxes at ₹0.10 million.
The company's market cap is ₹2,307 crore, with a stock price of ₹135. The historical stock range has been between ₹148 / 80.5. Its Price-to-Earnings (P/E) ratio of 30.3 indicates a high valuation. The book value per share is ₹75.0, and it has a dividend yield of 0.00%. The ROCE is 10.3% and ROE is 6.09%. With a very low debt-to-equity ratio of 0.51, the company is minimally leveraged. However, it reports a negative net cash flow of ₹35.0 crore. The Piotroski score of 8.00 and the Graham Number of ₹86.9 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 1.81 suggests the stock is trading at a premium.
Eris Lifesciences Limited
4,566.90
Net Sales
170.40
Net Profit
4,618.50
Total Income
4,350.30
Expenditure
1,448
Current Price
19,711
Market Cap
In Eris Lifesciences Limited's recent financial report, the data highlights a robust performance. Net sales reached ₹4,566.90 million, with total income of ₹4,618.50 million. The expenditure was ₹4,350.30 million, leading to a net profit of ₹170.40 million. Earnings per Share (EPS) for continuing operations were reported at ₹1.25. The financial overview also includes other income of ₹51.60 million, finance costs of ₹561.70 million, and employee benefit expenses totaling ₹1,037.50 million. Depreciation and amortization expenses were ₹455.50 million. Current and deferred taxes were recorded at ₹46.90 million and ₹50.90 million, respectively. The total comprehensive income for the period was ₹163.20 million, and other comprehensive income net of taxes was ₹-7.20 million.
Currently valued at ₹19,711 crore, the company's stock price is ₹1,448. It has seen a price range of ₹1,522 / 792 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 52.2, implying a strong valuation. The book value per share is ₹190 and the dividend yield is 0.51%. ROCE is recorded at 11.3%, and ROE stands at 16.3%. The company maintains a very low debt-to-equity ratio of 1.08, though it has a negative net cash flow of ₹38.2 crore. The Piotroski score of 4.00 and the Graham Number of ₹346 suggest some caution, while the Price-to-Book (P/B) ratio of 7.62 reflects a premium valuation.
Niit Learning Systems Limited
4,072.29
Net Sales
600.19
Net Profit
4,165.75
Total Income
3,324.23
Expenditure
525
Current Price
7,132
Market Cap
In Niit Learning Systems Limited's recent financial report, the data highlights a robust performance. Net sales reached ₹4,072.29 million, with total income of ₹4,165.75 million. The expenditure was ₹3,324.23 million, leading to a net profit of ₹600.19 million. Earnings per Share (EPS) for continuing operations were reported at ₹4.43. The financial overview also includes other income of ₹93.46 million, finance costs of ₹72.10 million, and employee benefit expenses totaling ₹1,950.11 million. Depreciation and amortization expenses were ₹139.97 million. Current and deferred taxes were recorded at ₹178.72 million and ₹33.56 million, respectively. The total comprehensive income for the period was ₹586.88 million, and other comprehensive income net of taxes was ₹-13.31 million.
Valued at ₹7,132 crore, the company's stock trades at ₹525, with historical highs and lows of ₹577 / 342. The P/E ratio of 32.0 reflects a high stock valuation. The book value is ₹72.2, and the dividend yield is 0.99%. ROCE is at 33.6%, and ROE is 24.8%. The company’s minimal debt-to-equity ratio of 0.14 contrasts with its negative net cash flow of ₹28.4 crore. The Piotroski score is 6.00, and the Graham Number of ₹162 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 7.26 indicates a premium valuation.
V2 Retail Limited
4,150.33
Net Sales
163.40
Net Profit
4,164.26
Total Income
3,946.56
Expenditure
1,091
Current Price
3,772
Market Cap
The financial snapshot for V2 Retail Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹4,150.33 million and total income was ₹4,164.26 million. The company's expenditure was ₹3,946.56 million, leading to a net profit of ₹163.40 million. Earnings per Share (EPS) for continuing operations were ₹4.72. The report also highlights other income of ₹13.93 million, finance costs of ₹137.13 million, and employee benefit expenses of ₹356.19 million. Depreciation and amortization costs were ₹213.68 million, while current and deferred taxes were ₹50.34 million and ₹3.96 million, respectively. The total comprehensive income for the period stood at ₹161.90 million, with other comprehensive income net of taxes at ₹-1.50 million.
The company's market cap is ₹3,772 crore, with a stock price of ₹1,091. The historical stock range has been between ₹1,247 / 133. Its Price-to-Earnings (P/E) ratio of 99.8 indicates a high valuation. The book value per share is ₹79.4, and it has a dividend yield of 0.00%. The ROCE is 10.7% and ROE is 10.7%. With a very low debt-to-equity ratio of 1.91, the company is minimally leveraged. However, it reports a negative net cash flow of ₹4.53 crore. The Piotroski score of 7.00 and the Graham Number of ₹140 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 13.7 suggests the stock is trading at a premium.
Kalyan Jewellers India Limited
55,354.79
Net Sales
1,775.58
Net Profit
55,576.37
Total Income
53,201.46
Expenditure
643
Current Price
66,324
Market Cap
The latest financial figures for Kalyan Jewellers India Limited indicate a strong performance. The company achieved net sales of ₹55,354.79 million and total income of ₹55,576.37 million for the quarter. Expenditure was ₹53,201.46 million, resulting in a net profit of ₹1,775.58 million. Earnings per Share (EPS) for continuing operations stood at ₹1.73. The report also shows other income of ₹221.58 million, finance costs of ₹852.25 million, and employee benefit expenses of ₹1,724.32 million. Depreciation and amortization expenses totaled ₹754.69 million. Current tax expense was ₹894.99 million and deferred tax expense was ₹-295.66 million. Total comprehensive income for the period was ₹1,757.02 million, with other comprehensive income net of taxes at ₹-18.56 million.
Valued at ₹66,324 crore, the company's stock trades at ₹643, with historical highs and lows of ₹663 / 203. The P/E ratio of 105 reflects a high stock valuation. The book value is ₹40.7, and the dividend yield is 0.19%. ROCE is at 14.0%, and ROE is 15.2%. The company’s minimal debt-to-equity ratio of 1.07 contrasts with its negative net cash flow of ₹36.8 crore. The Piotroski score is 7.00, and the Graham Number of ₹74.9 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 15.8 indicates a premium valuation.
Sanjivani Paranteral Ltd.
0.00
Net Sales
17.14
Net Profit
165.23
Total Income
-142.49
Expenditure
214
Current Price
250
Market Cap
In Sanjivani Paranteral Ltd.'s recent financial report, the data highlights a robust performance. Net sales reached ₹0.00 million, with total income of ₹165.23 million. The expenditure was ₹-142.49 million, leading to a net profit of ₹17.14 million. Earnings per Share (EPS) for continuing operations were reported at ₹1.47. The financial overview also includes other income of ₹0.86 million, finance costs of ₹-0.16 million, and employee benefit expenses totaling ₹-11.27 million. Depreciation and amortization expenses were ₹-1.33 million. Current and deferred taxes were recorded at ₹-5.60 million and ₹0.00 million, respectively. The total comprehensive income for the period was ₹0.00 million, and other comprehensive income net of taxes was ₹0.00 million.
The company's market cap is ₹250 crore, with a stock price of ₹214. The historical stock range has been between ₹233 / 62.0. Its Price-to-Earnings (P/E) ratio of 40.5 indicates a high valuation. The book value per share is ₹23.9, and it has a dividend yield of 0.00%. The ROCE is 55.3% and ROE is 49.7%. With a very low debt-to-equity ratio of 0.03, the company is minimally leveraged. However, it reports a negative net cash flow of ₹0.24 crore. The Piotroski score of 4.00 and the Graham Number of ₹53.2 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 8.98 suggests the stock is trading at a premium.
Alkem Laboratories Limited
25,001.00
Net Sales
5,832.50
Net Profit
26,062.00
Total Income
19,652.60
Expenditure
6,310
Current Price
75,445
Market Cap
The latest financial figures for Alkem Laboratories Limited indicate a strong performance. The company achieved net sales of ₹25,001.00 million and total income of ₹26,062.00 million for the quarter. Expenditure was ₹19,652.60 million, resulting in a net profit of ₹5,832.50 million. Earnings per Share (EPS) for continuing operations stood at ₹48.78. The report also shows other income of ₹1,061.00 million, finance costs of ₹214.40 million, and employee benefit expenses of ₹4,259.00 million. Depreciation and amortization expenses totaled ₹643.50 million. Current tax expense was ₹1,112.60 million and deferred tax expense was ₹-535.70 million. Total comprehensive income for the period was ₹5,807.70 million, with other comprehensive income net of taxes at ₹-24.80 million.
Valued at ₹75,445 crore, the company's stock trades at ₹6,310, with historical highs and lows of ₹6,347 / 3,440. The P/E ratio of 35.2 reflects a high stock valuation. The book value is ₹862, and the dividend yield is 0.63%. ROCE is at 19.7%, and ROE is 19.6%. The company’s minimal debt-to-equity ratio of 0.14 contrasts with its negative net cash flow of ₹-207 crore. The Piotroski score is 9.00, and the Graham Number of ₹1,826 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 7.32 indicates a premium valuation.